UBS raised the firm’s price target on Medtronic (MDT) to $102 from $95 and keeps a Neutral rating on the shares. Execution remains key for reacclerating organic sales growth, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $109 from $103 at Baird
- Medtronic price target raised to $114 from $100 at Wells Fargo
- Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects
- Medtronic price target raised to $111 from $98 at Bernstein
- Medtronic’s Strategic Growth and Cautious Optimism Amid Fiscal Gains and Investment Needs